Exon-level microarray analyses identify alternative splicing programs in breast cancer

Anna Lapuk, Henry Marr, Lakshmi Jakkula, Helder Pedro, Sanchita Bhattacharya, Elizabeth Purdom, Zhi Hu, Ken Simpson, Lior Pachter, Steffen Durinck, Nicholas Wang, Bahram Parvin, Gerald Fontenay, Terence Speed, James Garbe, Martha Stampfer, Hovig Bayandorian, Shannon Dorton, Tyson A. Clark, Anthony SchweitzerAndrew Wyrobek, Heidi Feiler, Paul Spellman, John Conboy, Joe Gray

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Protein isoforms produced by alternative splicing (AS) of many genes have been implicated in several aspects of cancer genesis and progression. These observations motivated a genome-wide assessment of AS in breast cancer. We accomplished this by measuring exon level expression in 31 breast cancer and nonmalignant immortalized cell lines representing luminal, basal, and claudin-low breast cancer subtypes using Affymetrix Human Junction Arrays. We analyzed these data using a computational pipeline specifically designed to detect AS with a low false-positive rate. This identified 181 splice events representing 156 genes as candidates for AS. Reverse transcription-PCR validation of a subset of predicted AS events confirmed 90%. Approximately half of the AS events were associated with basal, luminal, or claudin-low breast cancer subtypes. Exons involved in claudin-low subtype-specific AS were significantly associated with the presence of evolutionarily conserved binding motifs for the tissue-specific Fox2 splicing factor. Small interfering RNA knockdown of Fox2 confirmed the involvement of this splicing factor in subtype-specific AS. The subtype-specific AS detected in this study likely reflects the splicing pattern in the breast cancer progenitor cells in which the tumor arose and suggests the utility of assays for Fox-mediated AS in cancer subtype definition and early detection. These data also suggest the possibility of reducing the toxicity of protein-targeted breast cancer treatments by targeting protein isoforms that are not present in limiting normal tissues.

Original languageEnglish (US)
Pages (from-to)961-974
Number of pages14
JournalMolecular Cancer Research
Volume8
Issue number7
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Alternative Splicing
Microarray Analysis
Exons
Breast Neoplasms
Protein Isoforms
Neoplasms
Small Interfering RNA
Genes
Reverse Transcription
Stem Cells
Genome
Cell Line
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Exon-level microarray analyses identify alternative splicing programs in breast cancer. / Lapuk, Anna; Marr, Henry; Jakkula, Lakshmi; Pedro, Helder; Bhattacharya, Sanchita; Purdom, Elizabeth; Hu, Zhi; Simpson, Ken; Pachter, Lior; Durinck, Steffen; Wang, Nicholas; Parvin, Bahram; Fontenay, Gerald; Speed, Terence; Garbe, James; Stampfer, Martha; Bayandorian, Hovig; Dorton, Shannon; Clark, Tyson A.; Schweitzer, Anthony; Wyrobek, Andrew; Feiler, Heidi; Spellman, Paul; Conboy, John; Gray, Joe.

In: Molecular Cancer Research, Vol. 8, No. 7, 07.2010, p. 961-974.

Research output: Contribution to journalArticle

Lapuk, A, Marr, H, Jakkula, L, Pedro, H, Bhattacharya, S, Purdom, E, Hu, Z, Simpson, K, Pachter, L, Durinck, S, Wang, N, Parvin, B, Fontenay, G, Speed, T, Garbe, J, Stampfer, M, Bayandorian, H, Dorton, S, Clark, TA, Schweitzer, A, Wyrobek, A, Feiler, H, Spellman, P, Conboy, J & Gray, J 2010, 'Exon-level microarray analyses identify alternative splicing programs in breast cancer', Molecular Cancer Research, vol. 8, no. 7, pp. 961-974. https://doi.org/10.1158/1541-7786.MCR-09-0528
Lapuk, Anna ; Marr, Henry ; Jakkula, Lakshmi ; Pedro, Helder ; Bhattacharya, Sanchita ; Purdom, Elizabeth ; Hu, Zhi ; Simpson, Ken ; Pachter, Lior ; Durinck, Steffen ; Wang, Nicholas ; Parvin, Bahram ; Fontenay, Gerald ; Speed, Terence ; Garbe, James ; Stampfer, Martha ; Bayandorian, Hovig ; Dorton, Shannon ; Clark, Tyson A. ; Schweitzer, Anthony ; Wyrobek, Andrew ; Feiler, Heidi ; Spellman, Paul ; Conboy, John ; Gray, Joe. / Exon-level microarray analyses identify alternative splicing programs in breast cancer. In: Molecular Cancer Research. 2010 ; Vol. 8, No. 7. pp. 961-974.
@article{403e9faf4ad945b2a581bf3819c1cade,
title = "Exon-level microarray analyses identify alternative splicing programs in breast cancer",
abstract = "Protein isoforms produced by alternative splicing (AS) of many genes have been implicated in several aspects of cancer genesis and progression. These observations motivated a genome-wide assessment of AS in breast cancer. We accomplished this by measuring exon level expression in 31 breast cancer and nonmalignant immortalized cell lines representing luminal, basal, and claudin-low breast cancer subtypes using Affymetrix Human Junction Arrays. We analyzed these data using a computational pipeline specifically designed to detect AS with a low false-positive rate. This identified 181 splice events representing 156 genes as candidates for AS. Reverse transcription-PCR validation of a subset of predicted AS events confirmed 90{\%}. Approximately half of the AS events were associated with basal, luminal, or claudin-low breast cancer subtypes. Exons involved in claudin-low subtype-specific AS were significantly associated with the presence of evolutionarily conserved binding motifs for the tissue-specific Fox2 splicing factor. Small interfering RNA knockdown of Fox2 confirmed the involvement of this splicing factor in subtype-specific AS. The subtype-specific AS detected in this study likely reflects the splicing pattern in the breast cancer progenitor cells in which the tumor arose and suggests the utility of assays for Fox-mediated AS in cancer subtype definition and early detection. These data also suggest the possibility of reducing the toxicity of protein-targeted breast cancer treatments by targeting protein isoforms that are not present in limiting normal tissues.",
author = "Anna Lapuk and Henry Marr and Lakshmi Jakkula and Helder Pedro and Sanchita Bhattacharya and Elizabeth Purdom and Zhi Hu and Ken Simpson and Lior Pachter and Steffen Durinck and Nicholas Wang and Bahram Parvin and Gerald Fontenay and Terence Speed and James Garbe and Martha Stampfer and Hovig Bayandorian and Shannon Dorton and Clark, {Tyson A.} and Anthony Schweitzer and Andrew Wyrobek and Heidi Feiler and Paul Spellman and John Conboy and Joe Gray",
year = "2010",
month = "7",
doi = "10.1158/1541-7786.MCR-09-0528",
language = "English (US)",
volume = "8",
pages = "961--974",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Exon-level microarray analyses identify alternative splicing programs in breast cancer

AU - Lapuk, Anna

AU - Marr, Henry

AU - Jakkula, Lakshmi

AU - Pedro, Helder

AU - Bhattacharya, Sanchita

AU - Purdom, Elizabeth

AU - Hu, Zhi

AU - Simpson, Ken

AU - Pachter, Lior

AU - Durinck, Steffen

AU - Wang, Nicholas

AU - Parvin, Bahram

AU - Fontenay, Gerald

AU - Speed, Terence

AU - Garbe, James

AU - Stampfer, Martha

AU - Bayandorian, Hovig

AU - Dorton, Shannon

AU - Clark, Tyson A.

AU - Schweitzer, Anthony

AU - Wyrobek, Andrew

AU - Feiler, Heidi

AU - Spellman, Paul

AU - Conboy, John

AU - Gray, Joe

PY - 2010/7

Y1 - 2010/7

N2 - Protein isoforms produced by alternative splicing (AS) of many genes have been implicated in several aspects of cancer genesis and progression. These observations motivated a genome-wide assessment of AS in breast cancer. We accomplished this by measuring exon level expression in 31 breast cancer and nonmalignant immortalized cell lines representing luminal, basal, and claudin-low breast cancer subtypes using Affymetrix Human Junction Arrays. We analyzed these data using a computational pipeline specifically designed to detect AS with a low false-positive rate. This identified 181 splice events representing 156 genes as candidates for AS. Reverse transcription-PCR validation of a subset of predicted AS events confirmed 90%. Approximately half of the AS events were associated with basal, luminal, or claudin-low breast cancer subtypes. Exons involved in claudin-low subtype-specific AS were significantly associated with the presence of evolutionarily conserved binding motifs for the tissue-specific Fox2 splicing factor. Small interfering RNA knockdown of Fox2 confirmed the involvement of this splicing factor in subtype-specific AS. The subtype-specific AS detected in this study likely reflects the splicing pattern in the breast cancer progenitor cells in which the tumor arose and suggests the utility of assays for Fox-mediated AS in cancer subtype definition and early detection. These data also suggest the possibility of reducing the toxicity of protein-targeted breast cancer treatments by targeting protein isoforms that are not present in limiting normal tissues.

AB - Protein isoforms produced by alternative splicing (AS) of many genes have been implicated in several aspects of cancer genesis and progression. These observations motivated a genome-wide assessment of AS in breast cancer. We accomplished this by measuring exon level expression in 31 breast cancer and nonmalignant immortalized cell lines representing luminal, basal, and claudin-low breast cancer subtypes using Affymetrix Human Junction Arrays. We analyzed these data using a computational pipeline specifically designed to detect AS with a low false-positive rate. This identified 181 splice events representing 156 genes as candidates for AS. Reverse transcription-PCR validation of a subset of predicted AS events confirmed 90%. Approximately half of the AS events were associated with basal, luminal, or claudin-low breast cancer subtypes. Exons involved in claudin-low subtype-specific AS were significantly associated with the presence of evolutionarily conserved binding motifs for the tissue-specific Fox2 splicing factor. Small interfering RNA knockdown of Fox2 confirmed the involvement of this splicing factor in subtype-specific AS. The subtype-specific AS detected in this study likely reflects the splicing pattern in the breast cancer progenitor cells in which the tumor arose and suggests the utility of assays for Fox-mediated AS in cancer subtype definition and early detection. These data also suggest the possibility of reducing the toxicity of protein-targeted breast cancer treatments by targeting protein isoforms that are not present in limiting normal tissues.

UR - http://www.scopus.com/inward/record.url?scp=77955463831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955463831&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-09-0528

DO - 10.1158/1541-7786.MCR-09-0528

M3 - Article

C2 - 20605923

AN - SCOPUS:77955463831

VL - 8

SP - 961

EP - 974

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 7

ER -